

ASX ANNOUNCEMENT

New TT-034 paper published in Nature

Sydney, Australia, 7th February 2014: RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that a scientific paper characterising the company's 'first in man' clinical therapeutic TT-034 (a ddRNAi-based therapeutic intended as a "single shot" cure for hepatitis C) has been published in the prestigious peer reviewed scientific journal *Nature Molecular Therapy - Nucleic Acids*. The title of the paper is entitled "Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision." The company announced on the 10th of December 2013 that the publication had been accepted; today's information confirms that the full text of this paper is now available in the February edition of the publication
<http://www.nature.com/mtna/journal/v3/n2/full/mtna201373a.html>

The paper is co-authored by Benitec's Senior Vice President of R&D, Dr David Suhy, along with scientists from Pfizer. This research came out of the collaboration between Tacere Therapeutics (acquired by Benitec in October 2012) and Pfizer which generated most of the pre-clinical work for TT-034 that was recently reviewed by as part of the Investigational New Drug application by the US Food and Drug Administration (USFDA).

For more information please contact: Dr Peter French | Chief Executive Officer and Managing Director
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About TT-034: TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance, a major problem for most hepatitis C drugs, by simultaneously silencing three separate highly conserved regions on the virus genome. Animal studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.